A Detailed Protocol for Constructing a Human Single-Chain Variable Fragment (scFv) Library and Downstream Screening Via Phage Display

Overview

Journal Methods Protoc

Specialty General Medicine

Date 2024 Feb 23

PMID 38392687

Authors

Ziyi Liu

Dokyun Kim

Seokmin Kang

Jae U Jung

Affiliations

Soon will be listed here.

Abstract

The development of monoclonal antibodies (mAbs) represents a significant milestone in both basic research and clinical applications due to their target specificity and versatility in therapeutic and diagnostic applications. The innovative strategy of mAb screening, utilizing phage display, facilitates the in vitro screening of antibodies with high affinity to target antigens. The single-chain variable fragment (scFv) is a subset of mAb derivatives, known for its high binding affinity and smaller size-just one-third of that of human IgG. This report outlines a detailed and comprehensive procedure for constructing a scFv phagemid library derived from human patients, followed by screening via phage display affinity selection. The protocol utilizes 348 primer combinations spanning the entire human antibody repertoire to minimize sequence bias and maintain library diversity during polymerase chain reaction (PCR) for scFv generation, resulting in a library size greater than 1 × 10. Furthermore, we describe a high-throughput phage display screening protocol using enzyme-linked immunosorbent assay (ELISA) to evaluate more than 1200 scFv candidates. The generation of a highly diverse scFv library, coupled with the implementation of a phage display screening methodology, is expected to provide a valuable resource for researchers in pursuit of scFvs with high affinity for target antigens, thus advancing both research and clinical endeavors.

References

Zhou H, Zhang Y, Lu G, Ji H, Rodi C . Recombinant antibody libraries and selection technologies. N Biotechnol. 2011; 28(5):448-52. DOI: 10.1016/j.nbt.2011.03.013. View

Kohler G, Milstein C . Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975; 256(5517):495-7. DOI: 10.1038/256495a0. View

Nahta R, Esteva F . Trastuzumab: triumphs and tribulations. Oncogene. 2007; 26(25):3637-43. DOI: 10.1038/sj.onc.1210379. View

Bird R, HARDMAN K, Jacobson J, Johnson S, Kaufman B, Lee S . Single-chain antigen-binding proteins. Science. 1988; 242(4877):423-6. DOI: 10.1126/science.3140379. View

Hoogenboom H . Selecting and screening recombinant antibody libraries. Nat Biotechnol. 2005; 23(9):1105-16. DOI: 10.1038/nbt1126. View

Gu X, Jia X, Feng J, Shen B, Huang Y, Geng S . Molecular modeling and affinity determination of scFv antibody: proper linker peptide enhances its activity. Ann Biomed Eng. 2009; 38(2):537-49. DOI: 10.1007/s10439-009-9810-2. View

Hansel T, Kropshofer H, Singer T, Mitchell J, George A . The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010; 9(4):325-38. DOI: 10.1038/nrd3003. View

Zhao Q, Buhr D, Gunter C, Frenette J, Ferguson M, Sanford E . Rational library design by functional CDR resampling. N Biotechnol. 2017; 45:89-97. PMC: 5995609. DOI: 10.1016/j.nbt.2017.12.005. View

Duan Y, Chen R, Huang Y, Meng X, Chen J, Liao C . Tuning the ignition of CAR: optimizing the affinity of scFv to improve CAR-T therapy. Cell Mol Life Sci. 2021; 79(1):14. PMC: 11073403. DOI: 10.1007/s00018-021-04089-x. View

10.

Safdari Y, Farajnia S, Asgharzadeh M, Khalili M . Antibody humanization methods - a review and update. Biotechnol Genet Eng Rev. 2014; 29:175-86. DOI: 10.1080/02648725.2013.801235. View

11.

Kanekiyo M, Bu W, Joyce M, Meng G, Whittle J, Baxa U . Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site. Cell. 2015; 162(5):1090-100. PMC: 4757492. DOI: 10.1016/j.cell.2015.07.043. View

12.

Lerner R . Combinatorial antibody libraries: new advances, new immunological insights. Nat Rev Immunol. 2016; 16(8):498-508. DOI: 10.1038/nri.2016.67. View

13.

Zhao S, Chadwick L, Mysler E, Moots R . Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis. Curr Rheumatol Rep. 2018; 20(10):57. PMC: 6097048. DOI: 10.1007/s11926-018-0769-6. View

14.

Wang S, Yan Y, Ho K . US FDA-approved therapeutic antibodies with high-concentration formulation: summaries and perspectives. Antib Ther. 2021; 4(4):262-272. PMC: 8664682. DOI: 10.1093/abt/tbab027. View

15.

Bazan J, Calkosinski I, Gamian A . Phage display--a powerful technique for immunotherapy: 1. Introduction and potential of therapeutic applications. Hum Vaccin Immunother. 2012; 8(12):1817-28. PMC: 3656071. DOI: 10.4161/hv.21703. View

16.

Wang S, Zheng C, Liu Y, Zheng H, Wang Z . Construction of multiform scFv antibodies using linker peptide. J Genet Genomics. 2008; 35(5):313-6. DOI: 10.1016/S1673-8527(08)60045-4. View

17.

Pardon E, Laeremans T, Triest S, Rasmussen S, Wohlkonig A, Ruf A . A general protocol for the generation of Nanobodies for structural biology. Nat Protoc. 2014; 9(3):674-93. PMC: 4297639. DOI: 10.1038/nprot.2014.039. View

18.

Schladetsch M, Wiemer A . Generation of Single-Chain Variable Fragment (scFv) Libraries for Use in Phage Display. Curr Protoc. 2021; 1(7):e182. DOI: 10.1002/cpz1.182. View

19.

Rader C, Barbas 3rd C . Phage display of combinatorial antibody libraries. Curr Opin Biotechnol. 1997; 8(4):503-8. DOI: 10.1016/s0958-1669(97)80075-4. View

20.

Ahmad Z, Yeap S, Ali A, Ho W, Mohamed Alitheen N, Hamid M . scFv antibody: principles and clinical application. Clin Dev Immunol. 2012; 2012:980250. PMC: 3312285. DOI: 10.1155/2012/980250. View